The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study

[1]  R. Wermers,et al.  The Eucalcemic Patient With Elevated Parathyroid Hormone Levels , 2023, Journal of the Endocrine Society.

[2]  H. McNulty,et al.  A 2‐Year Randomized Controlled Trial With Low‐Dose B‐Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status , 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  J. Twisk,et al.  Modeling non-linear relationships in epidemiological data: The application and interpretation of spline models , 2022, Frontiers in Epidemiology.

[4]  T. Huppertz,et al.  Calcium Absorption from Food Products: Food Matrix Effects , 2021, Nutrients.

[5]  J. Payer,et al.  Parathyroid Hormone-Related Changes of Bone Structure. , 2021, Physiological research.

[6]  H. McNulty,et al.  Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults , 2021, The American journal of clinical nutrition.

[7]  P. Trimboli,et al.  Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature , 2021, International journal of endocrinology.

[8]  J. Reginster,et al.  Fragility fractures in Europe: burden, management and opportunities , 2020, Archives of Osteoporosis.

[9]  S. Pearson,et al.  Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013–2016 , 2020, Therapeutic advances in gastroenterology.

[10]  G. Omrani,et al.  The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density , 2019, Risk management and healthcare policy.

[11]  S. Ima-Nirwana,et al.  Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved , 2019, International journal of environmental research and public health.

[12]  J. Quinlan,et al.  Changing trends in the mortality rate at 1-year post hip fracture - a systematic review , 2019, World journal of orthopedics.

[13]  Hsuan-Chia Yang,et al.  Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies , 2018, Osteoporosis International.

[14]  Yousef Nassar,et al.  Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis , 2018, Journal of bone metabolism.

[15]  D. Freedberg,et al.  The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. , 2017, Gastroenterology.

[16]  H. McNulty,et al.  Dairy intakes in older Irish adults and effects on vitamin micronutrient status: Data from the TUDA study , 2016, Proceedings of the Nutrition Society.

[17]  A. Arj,et al.  Proton pump inhibitors use and change in bone mineral density , 2016, International journal of rheumatic diseases.

[18]  Kreshnik Hoti,et al.  Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors , 2016, Journal of Bone and Mineral Metabolism.

[19]  B. Stack,et al.  Hyperparathyroidism Associated with Long‐Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults , 2015, Journal of the American Geriatrics Society.

[20]  H. McNulty,et al.  Determinants of 25-hydroxyvitamin D in older Irish adults. , 2015, Age and ageing.

[21]  J. Bilezikian,et al.  Parathyroid hormone: anabolic and catabolic actions on the skeleton. , 2015, Current opinion in pharmacology.

[22]  P. Moayyedi,et al.  Proton Pump Inhibitors and Risk of Bone Fractures , 2014, Current Treatment Options in Gastroenterology.

[23]  I. Fogelman,et al.  Vitamin D Status and Parathyroid Hormone Concentrations Influence the Skeletal Response to Zoledronate and Denosumab , 2014, Calcified Tissue International.

[24]  H. Song,et al.  A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate , 2013, Journal of Gastroenterology.

[25]  S. Jamal,et al.  The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos) , 2012, The American Journal of Gastroenterology.

[26]  R. Eastell,et al.  Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.

[27]  K. O’Brien,et al.  Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  M. Lindstrom,et al.  Do Proton Pump Inhibitors Decrease Calcium Absorption? , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  J. Manson,et al.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. , 2010, Archives of internal medicine.

[30]  A. Giusti,et al.  Secondary Hyperparathyroidism Due to Hypovitaminosis D Affects Bone Mineral Density Response to Alendronate in Elderly Women with Osteoporosis: A Randomized Controlled Trial , 2007, Journal of the American Geriatrics Society.

[31]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[32]  A. Murray,et al.  Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.

[33]  P. Lips,et al.  Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. , 2001, Endocrine reviews.

[34]  C. Stedman,et al.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[35]  S. Cummings,et al.  Low Fractional Calcium Absorption Increases the Risk for Hip Fracture in Women with Low Calcium Intake , 2000, Annals of Internal Medicine.

[36]  Dammann,et al.  The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers , 1999, Alimentary pharmacology & therapeutics.

[37]  C. Donangelo,et al.  Calcium and osteoporosis. , 1997, Archivos latinoamericanos de nutricion.

[38]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[39]  K. Jordan,et al.  THE EPIDEMIOLOGY OF OSTEOPOROSIS , 1996, The British journal of clinical practice.

[40]  F. Sundler,et al.  Growth of the parathyroid glands in omeprazole-treated chickens. , 1994, Scandinavian journal of gastroenterology.

[41]  K. Abe,et al.  Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans , 1993, Calcified Tissue International.

[42]  E. Savarino,et al.  The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.

[43]  Y. Huang,et al.  Proton-pump inhibitors and risk of fractures: an update meta-analysis , 2015, Osteoporosis International.

[44]  G. McMahon,et al.  Association of loop diuretic use with higher parathyroid hormone levels in patients with normal renal function. , 2015, JAMA internal medicine.

[45]  S. Kopic,et al.  Gastric acid, calcium absorption, and their impact on bone health. , 2013, Physiological reviews.

[46]  J. Sundsfjord,et al.  Serum parathyroid hormone (PTH) levels in smokers and non-smokers. The fifth Tromsø study. , 2005, European journal of endocrinology.

[47]  M. Horowitz,et al.  Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures , 2004, Osteoporosis International.

[48]  S. Cummings,et al.  Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. , 2000, Annals of internal medicine.

[49]  C. Ponticelli,et al.  Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  S. Ljunghall,et al.  Evaluation of parathyroid function in patients with hypergastrinaemia and pernicious anaemia. , 1982, Upsala journal of medical sciences.

[51]  L. Grimelius,et al.  The parathyroid glands in experimentally induced hypergastrinemia in the rat. , 1977, Scandinavian journal of gastroenterology.